Oscar Health, Inc. (NYSE:OSCR – Get Free Report) Director Elbert O. Jr. Robinson sold 25,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $17.05, for a total value of $426,250.00. Following the completion of the transaction, the director now directly owns 89,512 shares in the company, valued at approximately $1,526,179.60. This trade represents a 21.83 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
Oscar Health Trading Down 2.0 %
Shares of OSCR opened at $15.98 on Friday. The stock has a fifty day moving average of $17.90 and a two-hundred day moving average of $18.20. The company has a debt-to-equity ratio of 0.26, a quick ratio of 0.73 and a current ratio of 0.73. The company has a market capitalization of $3.95 billion, a PE ratio of -266.33 and a beta of 1.67. Oscar Health, Inc. has a fifty-two week low of $7.29 and a fifty-two week high of $23.79.
Oscar Health (NYSE:OSCR – Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.02). The business had revenue of $2.42 billion during the quarter, compared to analyst estimates of $2.33 billion. Oscar Health had a net margin of 0.35% and a return on equity of 2.79%. The company’s revenue was up 68.3% on a year-over-year basis. During the same quarter last year, the firm posted ($0.29) earnings per share. As a group, analysts forecast that Oscar Health, Inc. will post -0.01 EPS for the current year.
Institutional Trading of Oscar Health
Wall Street Analysts Forecast Growth
Several equities analysts recently commented on the company. UBS Group assumed coverage on Oscar Health in a report on Monday, October 7th. They issued a “neutral” rating and a $23.00 target price on the stock. Bank of America downgraded shares of Oscar Health from a “neutral” rating to an “underperform” rating and reduced their price objective for the company from $21.00 to $13.50 in a research report on Wednesday, November 6th. Finally, Piper Sandler restated an “overweight” rating and issued a $28.00 price objective on shares of Oscar Health in a research report on Tuesday, September 10th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $22.93.
Get Our Latest Stock Report on Oscar Health
About Oscar Health
Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.
Featured Stories
- Five stocks we like better than Oscar Health
- What is Insider Trading? What You Can Learn from Insider Trading
- Vertiv’s Cool Tech Makes Its Stock Red-Hot
- Low PE Growth Stocks: Unlocking Investment Opportunities
- MarketBeat Week in Review – 11/18 – 11/22
- Why Are Stock Sectors Important to Successful Investing?
- 2 Finance Stocks With Competitive Advantages You Can’t Ignore
Receive News & Ratings for Oscar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oscar Health and related companies with MarketBeat.com's FREE daily email newsletter.